Biotie provides portfolio update on tozadenant BIOTIE

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 20, 2015 at 2:15 AM

Biotie provides portfolio update on tozadenant

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 20 February 2015 at 9.00 a.m. Biotie provides portfolio update on tozadenant Biotie announces further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease (PD). Biotie plans to conduct one Phase 3 study in 882 PD patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations) in which participants will be randomized in a double-blind manner to receive twice daily doses of 60mg or 120mg of tozadenant or placebo in addition to their standard anti-PD medications, for 24 weeks. The primary endpoint will be time spent in the "off" state in patients taking tozadenant as compared to placebo between baseline and week 24. Secondary endpoints will include "on" time without troublesome dyskinesia, the Unified Parkinson's Disease Rating Scale, Clinical Global Impression of Change and Patient Global Impression of Change. The placebo-controlled period will be followed by a 52 week open label treatment period to collect additional clinical safety data. The planned Phase 3 study is expected to start recruiting patients in the United States, Canada and selected European countries in the middle of 2015. Based on current estimates, top-line data is expected to be available by the end of 2018. Biotie has previously reported positive data from a 420-patient Phase 2b study evaluating tozadenant in PD patients experiencing levodopa related end-of-dose 'wearing-off'. Full data from this trial was published in Lancet Neurology in 2014(1). The trial met its primary endpoint of a highly significant decrease in "off" time vs. placebo, as well as demonstrating efficacy across multiple secondary endpoints. The Phase 3 protocol will largely replicate that of the Phase 2b study. Biotie expects that the published Phase 2b study will be considered the first of two pivotal studies required for registration for tozadenant in PD patients with end-of-dose 'wearing-off'. Biotie is considering financing options which may involve a capital raise to fully fund the tozadenant Phase 3 program to approval. Turku, 20 February 2015 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Dr. Stephen Bandak, Chief Medical Officer tel. +1 650 296 0946 (Pacific Time zone), email: stephen.bandak@biotie.com Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com www.biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main Media About tozadenant (SYN115) Tozadenant is an oral, potent and selective adenosine A2a receptor antagonist being developed for the treatment of Parkinson's disease. Tozadenant has displayed clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation metrics, in a 420 patient Phase 2b study completed in December 2012, and it is currently transitioning into Phase 3 development. About Parkinson's disease Parkinson's disease is the second most common neurodegenerative disorder, after Alzheimer's disease. It affects about one percent of people ages 65-69, rising to up to three percent of people who are 80 years and older. The symptoms of Parkinson's disease result from decreased dopamine production in regions of the brain controlling movement. About Biotie Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and three additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, cocaine dependence, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. (1) Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6. Epub 2014 Jul 6. [HUG#1895893]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

City National Bank Names New VP for Real Estate

Banking on Growth with Jeffrey LaBauve Jeffery LaBauve struts into the picture, ready to take the helm as City National Bank's new head of Commercial Real Estate Banking. And let me tell ya, the word on the street is he's raring to ramp things up. After almost two decades at Comerica Bank, this guy’s not here for a measly lap around the track—he's got plans to double...

Revolutionary Sports Ball Backpack: A Game Changer?

Backpacks Reinvented by a Clever Mom Ever been caught in the whirlwind of juggling kids, sports gear, and school supplies? Well, one stay-at-home mom from Poway, California found herself in just such a predicament. She turned this everyday chaos into a creative solution by designing a unique Sports Ball Backpack. The idea came to her while managing a toddler, a newborn,...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

55 Broad Street's New Face: A $500M Revamp with RXR

Recapitalization: Changing the Game for 55 Broad Street Here we are again, watching yet another iconic Manhattan building redefine itself. This time, it's 55 Broad Street's turn, as Silverstein, MetroLoft, and RXR shake things up. Newmark Group, Inc. (NASDAQ: NMRK), the fiery real estate power player, orchestrated a dynamic transaction involving a $305 million financing...

Anderson University Sees Financial Turnaround Success

Anderson University, against all odds, is shaking up the financial narrative they’ve been stuck in for a while. It’s kind of like finding a $20 bill in an old coat—a nice surprise but it doesn’t happen every day. The university’s recent report on their financial progress is reminding folks that when it comes to fiscal discipline, sometimes you just need fresh...

Pine AI Unveils AI Studio & Real-World Call Feature

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

Duke Energy's Cooling Tips Amid Florida Cold Front

Weather Whiplash in Florida Prompts Energy Tips Florida's residents are in for a gust of chilly air as a cold front sweeps across the state, sending temperatures plummeting from the balmy 80s to brisk 30s and 40s in northern pockets. Central Florida ain't missing out on the chill either, expecting to dip a good dozen degrees below its usual seasonal warmth. Heads up,...

Bernard Lancaster Steps Up as Mammoth's New President

A New Era Under Bernard Lancaster at Mammoth Change is in the air for Mammoth Energy Services, as Bernard “Bernie” Lancaster takes the helm as President. His promotion on November 9, 2026, might not send shockwaves through Wall Street right away, but anyone holding an interest in NASDAQ:TUSK should take note. Lancaster's appointment is the kind of decision that...

Class Action Greenlighted Against Concordia for Title IX Violations

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

BIBIBOP Brings Good Vibes with OLIPOP Happy Hour

Boosting Midday Energy with BIBIBOP's New Promo Here we go, folks. BIBIBOP Asian Grill is dialing up the culinary energy just when you need it most. From November 16 to 22, during their Good Energy Happy Hour, they’re serving up a deal designed to pump some pep into your afternoon—free OLIPOP prebiotic soda with any regular bowl purchase. Just stroll into any of their...